BCAB

Company Overview — What Does BioAtla, Inc. Do?

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. BioAtla, Inc. (BCAB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jay M. Short and employs approximately 60 people. With a market capitalization of $11M, BCAB is one of the notable companies in the Healthcare sector.

BioAtla, Inc. (BCAB) Stock Rating — Avoid (April 2026)

As of April 2026, BioAtla, Inc. receives a Avoid rating with a composite score of 16.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.BCAB ranks #4,436 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BioAtla, Inc. ranks #838 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BCAB Stock Price and 52-Week Range

BioAtla, Inc. (BCAB) currently trades at $4.56. The stock gained $0.04 (0.9%) in the most recent trading session. The 52-week high for BCAB is $1.43, which means the stock is currently trading 218.9% from its annual peak. The 52-week low is $0.13, putting the stock 3407.7% above its annual trough. Recent trading volume was 19K shares, suggesting relatively thin trading activity.

Is BCAB Overvalued or Undervalued? — Valuation Analysis

BioAtla, Inc. (BCAB) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.21x, versus the sector average of 2.75x. The price-to-sales ratio is 0.70x, compared to 1.66x for the average Healthcare stock.

At current multiples, BioAtla, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

BioAtla, Inc. Profitability — ROE, Margins, and Quality Score

BioAtla, Inc. (BCAB) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -166.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -436.9% versus the sector average of -33.1%.

The operating margin is -102.5% (sector: -66.1%). Net profit margin stands at -96.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BCAB Debt, Balance Sheet, and Financial Health

BioAtla, Inc. has a debt-to-equity ratio of 138.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 0.37x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $8M.

BCAB has a beta of 1.22, meaning it is more volatile than the broader market — a $10,000 investment in BCAB would be expected to move 21.9% more than the S&P 500 on any given day. The stability factor score for BioAtla, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

BioAtla, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BioAtla, Inc. reported revenue of $11M and earnings per share (EPS) of $-1.01. Net income for the quarter was $-60M. Operating income came in at $-61M.

In FY 2025, BioAtla, Inc. reported revenue of $2M and earnings per share (EPS) of $-1.01. Net income for the quarter was $-60M. Revenue grew -81.8% year-over-year compared to FY 2024. Operating income came in at $-59M.

In Q3 2025, BioAtla, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.27. Net income for the quarter was $-16M. Operating income came in at $-14M.

In Q2 2025, BioAtla, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-19M. Operating income came in at $-19M.

Over the past 8 quarters, BioAtla, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $11M. Investors analyzing BCAB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BCAB Dividend Yield and Income Analysis

BioAtla, Inc. (BCAB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BCAB Momentum and Technical Analysis Profile

BioAtla, Inc. (BCAB) has a momentum factor score of 12/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

BCAB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BioAtla, Inc. (BCAB) ranks #838 out of 838 stocks based on the Blank Capital composite score. This places BCAB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BCAB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BCAB vs S&P 500 (SPY) comparison to assess how BioAtla, Inc. stacks up against the broader market across all factor dimensions.

BCAB Next Earnings Date

No upcoming earnings date has been announced for BioAtla, Inc. (BCAB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BCAB? — Investment Thesis Summary

The quantitative profile for BioAtla, Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Momentum is weak at 12/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, BioAtla, Inc. (BCAB) earns a Avoid rating with a composite score of 16.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BCAB stock.

Related Resources for BCAB Investors

Explore more research and tools: BCAB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BCAB head-to-head with peers: BCAB vs AZN, BCAB vs SLGL, BCAB vs VMD.